难以治疗的Acinetobacter感染的挑战
Guy A Richards1, Olga Perovic2, Adrian J Brink3
1Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Clinical microbiology reviews
|November 18, 2024
概括
由于抗生素耐药性,治疗Acinetobacter感染具有挑战性. 本综述指导临床医生有关相关培养和治疗方法,强调对高死亡率感染的及时,有针对性的治疗.
科学领域:
- 传染性疾病 传染性疾病
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 这种细菌是Acinetobacter spp. 是难以治疗的病原体,已知具有多药性耐药性.
- 区分Acinetobacter殖民和活跃感染是一个临床挑战.
研究的目的:
- 审查对抗 Acinetobacter spp. 有效的抗生素.
- 为Acinetobacter感染提供有关培养和治疗策略的指导.
主要方法:
- 对针对Acinetobacter的抗生素进行文献审查.
- 诊断参数的分析,包括临床症状,生物标志物 (例如,前素) 和抗生素.
- 对抗性机制和最小抑制度 (MIC) 的评估.
主要成果:
- 几种抗生素对Acinetobacter spp.表现出活性.
- 抗生素和MIC对于选择适当的抗菌剂至关重要.
- 由于高可归因死亡率,建议立即针对性治疗.
结论:
- 对于Acinetobacter感染,通常建议使用组合治疗.
- 没有任何特定的组合疗法证明了绝对的优越性.
- 准确的诊断和及时的治疗对于改善患者的结果至关重要.
相关概念视频
Pneumonia IV: Management
299
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
299
Acute Respiratory Failure-V
123
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
123
Pulmonary Tuberculosis V
170
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
170
Development of Antibiotic Resistance
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
328
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
328
Cystic Fibrosis: Management
143
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
143


